Transformation-Related Questions (Main Survey)
| Section C | Question | Trigger/Risk | Response Count | Response Rate |
|---|---|---|---|---|
| Pharma Transformation Triggers | Q7 | Business Environment | 27 | 47% |
| Regulatory Environment | 20 | 35% | ||
| Open Innovation | 8 | 14% | ||
| Other (please specify): | 2 | 4% | ||
| Open Innovation | Q8 | Commercial Partnerships | 20 | 19% |
| Increased In-licensing | 17 | 16% | ||
| Research Partnerships | 13 | 12% | ||
| Research Information Sharing | 2 | 2% | ||
| Focus on Combination Products | 13 | 12% | ||
| Focus on Biological Products | 16 | 15% | ||
| Focus on Pervasive Technologies | 3 | 3% | ||
| Outsourcing of Data Management | 18 | 17% | ||
| Other (please Specify): | 3 | 3% | ||
| Pharma Transformation Risks | Q9 | Effective Due Diligence | 18 | 19% |
| Effective Product Transfer | 19 | 20% | ||
| Multidisciplinary Regulatory Knowledge | 13 | 14% | ||
| Effective Product Characterization | 16 | 17% | ||
| Data Security and Integrity | 9 | 10% | ||
| Technology Validation | 14 | 15% | ||
| Other (please Specify) | 4 | 4% |
Response rate varies by question since each respondent was allowed to choose multiple options for questions listed in column 2.